APOE and tauopathy: Compared to the PBS treatment, the mCRP treatment significantly induced the marker of neuronal tauopathy, shown by the immunostaining of pTau with the PFH‐1 antibody, in the neurons of the cortex (p < 0.01; Figure 3c) and hippocampus (p < 0.05; Figure 3d) in ApoE4 but not in ApoE3 or ApoE2 mice.